ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Symptom prevalence and pharmacological management of late-stage Parkinson's disease (LSPD): a cross-sectional, multinational survey.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late-stage Parkinson's disease (LSPD) presents with disabling motor and non-motor symptoms, the latter becoming dominant in the late stage. There is limited information on LSPD. This study aimed to identify common symptoms and common drug treatments of LSPD. We conducted an online survey of physicians treating patients with Parkinson's disease in specialized palliative care across Austria, Germany and Switzerland, followed by a two-round Delphi survey involving movement disorder specialists. Consensus was defined as ≥ 75% agreement. 118 participants of 1252 contacted institutions completed the survey. In the Delphi process, eight experts out of 19 participated. Most frequently reported symptoms were dysphagia (94%), rigidity (78%), speech disorder (70%), bradykinesia (61%), dementia (74%) and constipation (64%). Most frequently used medications for motor symptom control at admission to palliative care were levodopa (96%) and rotigotine (48%). Similarly, levodopa (64%) and rotigotine (49%) were most frequently reported to be prescribed until the end of palliative care. Delphi experts agreed on the importance of oral and intestinal levodopa as well as rotigotine for the palliative care phase. Levodopa therapy should be maintained until end of life. Regarding non-motor symptom control, Delphi panelists concluded that laxatives, antipsychotics and medications for hypersalivation should be administered until end of life. Macrogol (70%) and sodium picosulfate (71%) were the most favored laxatives. Among antipsychotics quetiapine was most recommended for psychosis (76%) and delirium (59%) management. However, Delphi panelists agreed on clozapine for psychosis management and quetiapine for delirium management. For hypersalivation, consensus was reached on botulinum toxin injection. harmacological treatment of LSPD should be based on a symptom-oriented and stage-based approach. Therapy encompasses levodopa and non-dopaminergic treatments for non-motor symptom control.
Indexed as
Identifiers
42627491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.